CI-988 (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "CI-988" in Serbian language version.

refsWebsite

Global rank Serbian rank

15nih.gov

4^th place

8^th place

14doi.org

2^nd place

4^th place

7semanticscholar.org

11^th place

23^rd place

2harvard.edu

18^th place

28^th place

doi.org

Hughes, J.; Boden, P.; Costall, B.; Domeney, A.; Kelly, E.; Horwell, D. C.; Hunter, J. C.; Pinnock, R. D.; Woodruff, G. N. (1990). „Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity”. Proceedings of the National Academy of Sciences of the United States of America. 1975695 (17): 6728—6732. Bibcode:1990PNAS...87.6728H. PMC 54610 . PMID 1975695. doi:10.1073/pnas.87.17.6728 .
Singh, L.; Field, M. J.; Hughes, J.; Menzies, R.; Oles, R. J.; Vass, C. A.; Woodruff, G. N. (1991). „The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist”. British Journal of Pharmacology. 1686205 (1): 239—245. PMC 1908271 . PMID 1686205. doi:10.1111/j.1476-5381.1991.tb12413.x.
Wiesenfeld-Hallin, Z.; Xu, X. J.; Hughes, J.; Horwell, D. C.; Hökfelt, T. (1990). „PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes”. Proceedings of the National Academy of Sciences of the United States of America. 1698290 (18): 7105—7109. Bibcode:1990PNAS...87.7105W. PMC 54692 . PMID 1698290. doi:10.1073/pnas.87.18.7105 .
Durieux, C.; Derrien, M.; Maldonado, R.; Valverde, O.; Blommaert, A.; Fournié-Zaluski, M. C.; Roques, B. P. (1994). „CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetration”. Annals of the New York Academy of Sciences. 8185186: 355—357. PMID 8185186. S2CID 23317834. doi:10.1111/j.1749-6632.1994.tb44091.x.
Xu, X. J.; Wiesenfeld-Hallin, Z.; Hughes, J.; Horwell, D. C.; Hökfelt, T. (1992). „CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat”. British Journal of Pharmacology. 1628146 (3): 591—596. PMC 1908430 . PMID 1628146. doi:10.1111/j.1476-5381.1992.tb09024.x.
Hoffmann, O.; Wiesenfeld-Hallin, Z. (1994). „The CCK-B receptor antagonist Cl 988 reverses tolerance to morphine in rats”. NeuroReport. 7696605 (18): 2565—2568. PMID 7696605. doi:10.1097/00001756-199412000-00040.
Maldonado, R.; Valverde, O.; Ducos, B.; Blommaert, A. G.; Fournie-Zaluski, M. C.; Roques, B. P. (1995). „Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308”. British Journal of Pharmacology. 7780637 (5): 1031—1039. PMC 1510310 . PMID 7780637. doi:10.1111/j.1476-5381.1995.tb13309.x.
Valverde, O.; Roques, B. P. (1998). „Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats”. Neuroscience Letters. 9578139 (1): 37—40. PMID 9578139. S2CID 34384142. doi:10.1016/s0304-3940(98)00118-9.
Bradwejn, J.; Koszycki, D.; Paradis, M.; Reece, P.; Hinton, J.; Sedman, A. (1995). „Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers”. Biological Psychiatry. 8580227 (11): 742—746. PMID 8580227. S2CID 1096074. doi:10.1016/0006-3223(95)00081-X.
Adams, J. B.; Pyke, R. E.; Costa, J.; Cutler, N. R.; Schweizer, E.; Wilcox, C. S.; Wisselink, P. G.; Greiner, M.; Pierce, M. W.; Pande, A. C. (1995). „A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder”. Journal of Clinical Psychopharmacology. 8748432 (6): 428—434. PMID 8748432. doi:10.1097/00004714-199512000-00007.
Van Megen, H. J.; Westenberg, H. G.; Den Boer, J. A.; Slaap, B.; Van Es-Radhakishun, F.; Pande, A. C. (1997). „The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients”. Psychopharmacology. 9084062 (3): 243—248. PMID 9084062. S2CID 12570838. doi:10.1007/s002130050186.
Goddard, A. W.; Woods, S. W.; Money, R.; Pande, A. C.; Charney, D. S.; Goodman, W. K.; Heninger, G. R.; Price, L. H. (1999). „Effects of the CCK(B) antagonist CI-988 on responses to MCPP in generalized anxiety disorder”. Psychiatry Research. 10333376 (3): 225—240. PMID 10333376. S2CID 140209273. doi:10.1016/s0165-1781(99)00015-3.
Pande, A. C.; Greiner, M.; Adams, J. B.; Lydiard, R. B.; Pierce, M. W. (1999). „Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder”. Biological Psychiatry. 10494457 (6): 860—862. PMID 10494457. S2CID 5801419. doi:10.1016/s0006-3223(99)00090-6.
Le Guen, S.; Mas Nieto, M.; Canestrelli, C.; Chen, H.; Fournié-Zaluski, M. C.; Cupo, A.; Maldonado, R.; Roques, B. P.; Noble, F. (2003). „Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: Long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone”. Pain. 12855323 (1–2): 139—148. PMID 12855323. S2CID 38514264. doi:10.1016/s0304-3959(02)00486-4.

harvard.edu

adsabs.harvard.edu

Hughes, J.; Boden, P.; Costall, B.; Domeney, A.; Kelly, E.; Horwell, D. C.; Hunter, J. C.; Pinnock, R. D.; Woodruff, G. N. (1990). „Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity”. Proceedings of the National Academy of Sciences of the United States of America. 1975695 (17): 6728—6732. Bibcode:1990PNAS...87.6728H. PMC 54610 . PMID 1975695. doi:10.1073/pnas.87.17.6728 .
Wiesenfeld-Hallin, Z.; Xu, X. J.; Hughes, J.; Horwell, D. C.; Hökfelt, T. (1990). „PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes”. Proceedings of the National Academy of Sciences of the United States of America. 1698290 (18): 7105—7109. Bibcode:1990PNAS...87.7105W. PMC 54692 . PMID 1698290. doi:10.1073/pnas.87.18.7105 .

nih.gov

ncbi.nlm.nih.gov

Hughes, J.; Boden, P.; Costall, B.; Domeney, A.; Kelly, E.; Horwell, D. C.; Hunter, J. C.; Pinnock, R. D.; Woodruff, G. N. (1990). „Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity”. Proceedings of the National Academy of Sciences of the United States of America. 1975695 (17): 6728—6732. Bibcode:1990PNAS...87.6728H. PMC 54610 . PMID 1975695. doi:10.1073/pnas.87.17.6728 .
Singh, L.; Field, M. J.; Hughes, J.; Menzies, R.; Oles, R. J.; Vass, C. A.; Woodruff, G. N. (1991). „The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist”. British Journal of Pharmacology. 1686205 (1): 239—245. PMC 1908271 . PMID 1686205. doi:10.1111/j.1476-5381.1991.tb12413.x.
Wiesenfeld-Hallin, Z.; Xu, X. J.; Hughes, J.; Horwell, D. C.; Hökfelt, T. (1990). „PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes”. Proceedings of the National Academy of Sciences of the United States of America. 1698290 (18): 7105—7109. Bibcode:1990PNAS...87.7105W. PMC 54692 . PMID 1698290. doi:10.1073/pnas.87.18.7105 .
Durieux, C.; Derrien, M.; Maldonado, R.; Valverde, O.; Blommaert, A.; Fournié-Zaluski, M. C.; Roques, B. P. (1994). „CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetration”. Annals of the New York Academy of Sciences. 8185186: 355—357. PMID 8185186. S2CID 23317834. doi:10.1111/j.1749-6632.1994.tb44091.x.
Valverde, O.; Maldonado, R.; Fournie-Zaluski, M. C.; Roques, B. P. (1994). „Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins”. The Journal of Pharmacology and Experimental Therapeutics. 8035345 (1): 77—88. PMID 8035345.
Xu, X. J.; Wiesenfeld-Hallin, Z.; Hughes, J.; Horwell, D. C.; Hökfelt, T. (1992). „CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat”. British Journal of Pharmacology. 1628146 (3): 591—596. PMC 1908430 . PMID 1628146. doi:10.1111/j.1476-5381.1992.tb09024.x.
Hoffmann, O.; Wiesenfeld-Hallin, Z. (1994). „The CCK-B receptor antagonist Cl 988 reverses tolerance to morphine in rats”. NeuroReport. 7696605 (18): 2565—2568. PMID 7696605. doi:10.1097/00001756-199412000-00040.
Maldonado, R.; Valverde, O.; Ducos, B.; Blommaert, A. G.; Fournie-Zaluski, M. C.; Roques, B. P. (1995). „Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308”. British Journal of Pharmacology. 7780637 (5): 1031—1039. PMC 1510310 . PMID 7780637. doi:10.1111/j.1476-5381.1995.tb13309.x.
Valverde, O.; Roques, B. P. (1998). „Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats”. Neuroscience Letters. 9578139 (1): 37—40. PMID 9578139. S2CID 34384142. doi:10.1016/s0304-3940(98)00118-9.
Bradwejn, J.; Koszycki, D.; Paradis, M.; Reece, P.; Hinton, J.; Sedman, A. (1995). „Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers”. Biological Psychiatry. 8580227 (11): 742—746. PMID 8580227. S2CID 1096074. doi:10.1016/0006-3223(95)00081-X.
Adams, J. B.; Pyke, R. E.; Costa, J.; Cutler, N. R.; Schweizer, E.; Wilcox, C. S.; Wisselink, P. G.; Greiner, M.; Pierce, M. W.; Pande, A. C. (1995). „A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder”. Journal of Clinical Psychopharmacology. 8748432 (6): 428—434. PMID 8748432. doi:10.1097/00004714-199512000-00007.
Van Megen, H. J.; Westenberg, H. G.; Den Boer, J. A.; Slaap, B.; Van Es-Radhakishun, F.; Pande, A. C. (1997). „The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients”. Psychopharmacology. 9084062 (3): 243—248. PMID 9084062. S2CID 12570838. doi:10.1007/s002130050186.
Goddard, A. W.; Woods, S. W.; Money, R.; Pande, A. C.; Charney, D. S.; Goodman, W. K.; Heninger, G. R.; Price, L. H. (1999). „Effects of the CCK(B) antagonist CI-988 on responses to MCPP in generalized anxiety disorder”. Psychiatry Research. 10333376 (3): 225—240. PMID 10333376. S2CID 140209273. doi:10.1016/s0165-1781(99)00015-3.
Pande, A. C.; Greiner, M.; Adams, J. B.; Lydiard, R. B.; Pierce, M. W. (1999). „Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder”. Biological Psychiatry. 10494457 (6): 860—862. PMID 10494457. S2CID 5801419. doi:10.1016/s0006-3223(99)00090-6.
Le Guen, S.; Mas Nieto, M.; Canestrelli, C.; Chen, H.; Fournié-Zaluski, M. C.; Cupo, A.; Maldonado, R.; Roques, B. P.; Noble, F. (2003). „Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: Long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone”. Pain. 12855323 (1–2): 139—148. PMID 12855323. S2CID 38514264. doi:10.1016/s0304-3959(02)00486-4.

semanticscholar.org

api.semanticscholar.org

Durieux, C.; Derrien, M.; Maldonado, R.; Valverde, O.; Blommaert, A.; Fournié-Zaluski, M. C.; Roques, B. P. (1994). „CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetration”. Annals of the New York Academy of Sciences. 8185186: 355—357. PMID 8185186. S2CID 23317834. doi:10.1111/j.1749-6632.1994.tb44091.x.
Valverde, O.; Roques, B. P. (1998). „Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats”. Neuroscience Letters. 9578139 (1): 37—40. PMID 9578139. S2CID 34384142. doi:10.1016/s0304-3940(98)00118-9.
Bradwejn, J.; Koszycki, D.; Paradis, M.; Reece, P.; Hinton, J.; Sedman, A. (1995). „Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers”. Biological Psychiatry. 8580227 (11): 742—746. PMID 8580227. S2CID 1096074. doi:10.1016/0006-3223(95)00081-X.
Van Megen, H. J.; Westenberg, H. G.; Den Boer, J. A.; Slaap, B.; Van Es-Radhakishun, F.; Pande, A. C. (1997). „The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients”. Psychopharmacology. 9084062 (3): 243—248. PMID 9084062. S2CID 12570838. doi:10.1007/s002130050186.
Goddard, A. W.; Woods, S. W.; Money, R.; Pande, A. C.; Charney, D. S.; Goodman, W. K.; Heninger, G. R.; Price, L. H. (1999). „Effects of the CCK(B) antagonist CI-988 on responses to MCPP in generalized anxiety disorder”. Psychiatry Research. 10333376 (3): 225—240. PMID 10333376. S2CID 140209273. doi:10.1016/s0165-1781(99)00015-3.
Pande, A. C.; Greiner, M.; Adams, J. B.; Lydiard, R. B.; Pierce, M. W. (1999). „Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder”. Biological Psychiatry. 10494457 (6): 860—862. PMID 10494457. S2CID 5801419. doi:10.1016/s0006-3223(99)00090-6.
Le Guen, S.; Mas Nieto, M.; Canestrelli, C.; Chen, H.; Fournié-Zaluski, M. C.; Cupo, A.; Maldonado, R.; Roques, B. P.; Noble, F. (2003). „Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: Long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone”. Pain. 12855323 (1–2): 139—148. PMID 12855323. S2CID 38514264. doi:10.1016/s0304-3959(02)00486-4.